Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome

The goal of this phase IV, open-label, randomized clinical trial is to evaluate whether intravenous iron improves quality of life in adults aged 65 years and older with iron deficiency after an acute coronary syndrome (ACS). The main questions it aims to answer are: * Does intravenous iron improve quality of life at 6 and 12 months? * Does it reduce frailty and adverse clinical outcomes? Researchers will compare intravenous ferric carboxymaltose with standard of care. Participants will: * Be randomly assigned to receive intravenous iron or standard care * Attend three study visits over 12 months * Complete questionnaires and undergo blood tests

NCT Number	NCT07476859
Lead Sponsor	Fundación para la Investigación del Hospital Clínico de Valencia Collaborators: AstraZeneca
Conditions	Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)
Enrollment	538 participants
Start Date	2026-03-05
Primary Completion	2028-04 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-03-24